bioAffinity Technologies, Inc. (BIAF)

bioAffinity Technologies' stock (BIAF) has experienced a stock price increase, with shares increasing by 72.0% since the beginning of the year. The company reported its first-quarter 2026 results, with a net loss of ($0.81) per share and revenue of $1.35 million, and full-year 2025 earnings showed a loss of US$8.66 per share. bioAffinity Technologies launched a new study to expand the use of CyPath® Lung technology for asthma and COPD diagnosis and treatment, and multiple case studies highlighting CyPath® Lung's effectiveness were published. The company initiated a large-scale, longitudinal clinical study for CyPath® Lung, partially funded by the U.S. Department of Defense. bioAffinity Technologies announced it had regained compliance with all applicable Nasdaq listing requirements, and the company's stock underwent a 1-for-30 reverse split on September 19, 2025. The company has been strategically discontinuing certain unprofitable pathology services to focus on higher-margin services, particularly CyPath® Lung testing.

Based on the available information, there is no explicit mention of significant demand seasonality for bioAffinity Technologies' products and services. The company has reported consistent growth in the adoption and sales of its CyPath® Lung test. This consistent growth and projected acceleration suggest a steady increase in demand rather than pronounced seasonal fluctuations. The demand is likely driven by ongoing efforts in commercialization, physician engagement, and the expansion of clinical studies, rather than specific times of the year.

bioAffinity Technologies, Inc. is a U.S.-based biotechnology company focused on non-invasive, early-stage cancer diagnosis and targeted cancer treatment, operating within the Biotechnology sector and the In Vitro Diagnostics industry. Its primary product, CyPath® Lung, is a non-invasive diagnostic test for early lung cancer detection, utilizing advanced flow cytometry and AI to analyze sputum samples. The company is also expanding its research and development to include diagnostic platforms for other lung diseases like asthma and COPD. bioAffinity Technologies operates through two segments: Diagnostic Research and Development, and Laboratory Services.

bioAffinity Technologies, Inc. is headquartered in San Antonio, Texas, United States, with operations and clinical studies primarily focused within the United States. A large-scale longitudinal clinical study for CyPath® Lung is being conducted with partial funding from the U.S. Department of Defense, involving up to 20 clinical sites, including Department of Veterans Affairs medical centers and leading U.S. military hospitals. The company is also focused on expanding into new geographic markets within the U.S.

bioAffinity Technologies' brand reputation is positively influenced by the growing adoption and clinical validation of its CyPath® Lung diagnostic test. The company has consistently highlighted the high sensitivity, specificity, and accuracy of CyPath® Lung in detecting early-stage lung cancer. The launch of a large-scale, longitudinal clinical study for CyPath® Lung enhances the test's credibility. The company's focus on non-invasive, early-stage cancer diagnosis addresses a significant unmet need. bioAffinity Technologies actively participates in scientific and medical forums, presenting data on CyPath® Lung and its diagnostic platform. The strategic decision to discontinue unprofitable pathology services to concentrate on the higher-margin CyPath® Lung test demonstrates a focused business strategy.

As of May 2026, institutional investors hold 1.64% of bioAffinity Technologies' stock, while insiders hold 2.68%. Public companies and retail investors hold the largest portion, at 94.10% of shares outstanding. Major institutional shareholders include Sabby Management LLC, J. Safra Sarasin Holding AG, Renaissance Technologies LLC, and others. Top mutual fund holders include Vanguard Index Funds - Vanguard Extended Market ETF and Vanguard Fiduciary Trust Co. Institutional Extended Market Index Trust Fund.